Neuroma, Acoustic clinical trials
The registry lists 100 studies for Neuroma, Acoustic across more than 10 countries. 28 are recruiting or about to start. 62 of them are mainly about Neuroma, Acoustic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its narrower condition Neurofibromatosis 2 too: 124 studies, 32 open.
Get an email when these change. Save the Neuroma, Acoustic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Beijing Tiantan Hospital (5) · Massachusetts Eye and Ear Infirmary (4) · Assistance Publique - Hôpitaux de Paris (3) · NYU Langone Health (3) · University Hospital Tuebingen (3) · Medical University of Vienna (3) · Assistance Publique Hopitaux De Marseille (2) · Central Hospital, Nancy, France (2)
What is being tested here
Drugs under test in Neuroma, Acoustic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| AZD 6244 | 2 | 0 | 3 |
| Luvometinib | 2 | 0 | 2 |
| Brigatinib | 1 | 0 | 1 |
| Neratinib | 1 | 0 | 1 |
| Retifanlimab | 1 | 0 | 1 |
| Panitumumab | 1 | 0 | 1 |
| IRDye800 | 1 | 0 | 1 |
| Oliceridine | 1 | 0 | 1 |
| Nimodipine | 1 | 0 | 1 |
| Bevacizumab | 0 | 0 | 3 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 1 open · Angiogenesis inhibitors 4
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 10
- Dec 2026Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma · Massachusetts General Hospital
- Dec 20263D MRE-Based Evaluation of Vestibular Schwannoma Mechanical Properties and Histological Features · Shengjing Hospital
- Dec 2026USPIO Enhanced MR Imaging in CNS Tumours (UMIC) · Northern Care Alliance NHS Foundation Trust
- Jan 2027CI Following VS Removal or Labyrinthectomy · Ohio State University
- Mar 2027StableEyes With Active Neurofeedback · Johns Hopkins University
- Mar 2027Study of Aspirin in Patients With Vestibular Schwannoma · Massachusetts Eye and Ear Infirmary
- Mar 2027Vestibular Rehabilitation Protocol in Unilateral Vestibular Schwannoma · Albert Torrents Torrero
- May 2027Early Rehabilitation Using Head Impulse Test for Acute Vestibular Deficit · Hospices Civils de Lyon
- Jul 2027Evaluating Pre-Treatment Vestibular Physical Therapy Rehab for Patients With Vestibular Schwannomas · Medical College of Wisconsin
- Aug 2027Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery · Xuanwu Hospital, Beijing
Who these studies take
Of the 22 Neuroma, Acoustic studies recruiting now, 9 (41%) set no upper age limit and 8 (36%) stop at 75 or younger. 3 (14%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (18%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (5%) | 1 (5%) |
| 18 | 21 (95%) | 21 (95%) |
| 30 | 22 (100%) | 22 (100%) |
| 40 | 22 (100%) | 22 (100%) |
| 50 | 22 (100%) | 22 (100%) |
| 65 | 22 (100%) | 22 (100%) |
| 75 | 16 (73%) | 16 (73%) |
| 85 | 14 (64%) | 14 (64%) |
Across all 100 studies, recruiting or not: 23% stop at 75 or younger and 11% at 65; 26% take children; 0% are for women only and 0% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Neuroma, Acoustic studies take
Of 24 interventional studies with no phase under Neuroma, Acoustic, half reached primary completion within 47 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Interventional, no phase | 47 mo35–146 · 24 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 14, 2026.
Started recruiting3
- Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma PatientsOct 26, 2026NCT07116811
- Mapping of Vestibular Centers Activation Using fMRI in Patients With Vestibular SchwannomaOct 22, 2026NCT07130851
- 3D MRE-Based Evaluation of Vestibular Schwannoma Mechanical Properties and Histological FeaturesOct 14, 2026NCT07844460
Studies
Recruiting first, then most recently updated. Showing 50 of 100. Browse all 100 → or search them.
- Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)RecruitingNCT04374305Phase 21 country
- Long Term Follow-up Study of AAVAnc80-antiVEGF Gene TherapyEnrolling by invitationNCT075036131 country
- Anti-VEGF Gene Therapy Trial for Vestibular SchwannomaRecruitingNCT06517888Phase 1/21 country
- Selumetinib for NF2-Related SchwannomatosisNot yet recruitingNCT07707947Phase 21 country
- Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma PatientsRecruitingNCT07116811Phase 31 country
- Mapping of Vestibular Centers Activation Using fMRI in Patients With Vestibular SchwannomaRecruitingNCT07130851Not applicable1 country
- Natural History Study of Patients With Neurofibromatosis Type 2RecruitingNCT005983511 country
- 3D MRE-Based Evaluation of Vestibular Schwannoma Mechanical Properties and Histological FeaturesRecruitingNCT078444601 country
- Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical ProceduresRecruitingNCT07493447Early Phase 11 country
- StableEyes With Active NeurofeedbackRecruitingNCT05622344Not applicable1 country
- Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular SchwannomaRecruitingNCT04859335Not applicable1 country
- Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)Not yet recruitingNCT07713745Phase 21 country
- Luvometinib in Combination With Serplulimab for NF2-Related TumorsNot yet recruitingNCT07708285Phase 1/21 country
- Measuring Vestibular Organ Function With Weak Alternating Current StimulationEnrolling by invitationNCT07267910Not applicable1 country
- Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle SurgeryRecruitingNCT07479446Not applicable1 country
- Evaluating Pre-Treatment Vestibular Physical Therapy Rehab for Patients With Vestibular SchwannomasRecruitingNCT05702749Not applicable1 country
- Vestibular Rehabilitation Protocol in Unilateral Vestibular SchwannomaRecruitingNCT07364955Not applicable1 country
- Early Rehabilitation Using Head Impulse Test for Acute Vestibular DeficitRecruitingNCT06660082Not applicable1 country
- Quality of Life and Decisional Regret in Patients Affected by Acoustic NeuromaRecruitingNCT068444611 country
- Radiosurgery Induced Ototoxicity in Patients Treated for a Vestibular SchwannomaRecruitingNCT056414411 country
- Intraoperative EABR for Decision MakingRecruitingNCT037455601 country
- Cochlear Implantation After Gamma Knife Radiosurgery with EABR and Correlation to Postoperative Hearing Results - a Pilot StudyRecruitingNCT037455341 country
- Evolution of Vestibular Function After Treatment of a Vestibular Schwannoma by Gamma-knife Radio-surgeryRecruitingNCT06112509Not applicable1 country
- USPIO Enhanced MR Imaging in CNS Tumours (UMIC)RecruitingNCT06572475Not applicable1 country
- 89Zr-Bevacizumab PET/CT Imaging in NF2 PatientsRecruitingNCT056858361 country
- MR Fingerprinting for Vestibular SchwannomasRecruitingNCT048519251 country
- Nimodipine in Vestibular SchwanommasRecruitingNCT04801953Phase 21 country
- Vestibular Precision: Physiology & PathophysiologyEnrolling by invitationNCT04890132Not applicable1 country
- Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and MeningiomaTerminatedNCT02282917Early Phase 11 country
- CI Following VS Removal or LabyrinthectomyActive, not recruitingNCT03795675Not applicable1 country
- Study of Aspirin in Patients With Vestibular SchwannomaActive, not recruitingNCT03079999Phase 21 country
- Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular SchwannomaActive, not recruitingNCT01199978Phase 21 country
- CyberKnife Radiotherapy for the Treatment of SchwannomasCompletedNCT078015601 country
- Cyberknife Radiosurgery for Patients With NeurinomasCompletedNCT02055859Not applicable1 country
- Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas SystemCompletedNCT04743310Phase 21 country
- Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular SchwannomaSuspendedNCT01083966Phase 11 country
- Vestibular Schwannoma OrganoidsCompletedNCT057861441 country
- Role of ChatGPT in Vestibular Schwannoma ManagementWithdrawnNCT06163664Not applicable
- Roy Adaptation Model Improves Mood and QOL After Giant Acoustic NeuromaCompletedNCT07305285Not applicable1 country
- Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast AgentCompletedNCT06322342Phase 21 country
- Maintaining Cochlear Patency After VIIIth Nerve SurgeryWithdrawnNCT03261726Not applicable1 country
- Use of DTT to Define Facial Nerve Position in Vestibular SchwannomasCompletedNCT04057976Not applicable1 country
- Trial of Selumetinib in Patients With Neurofibromatosis Type II Related TumorsTerminatedNCT03095248Phase 21 country
- Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular SchwannomaWithdrawnNCT04196933Not applicable1 country
- Vestibular Schwannoma - Radiosurgery or Expectation: V-REX.CompletedNCT02249572Not applicable1 country
- Longitudinal Recovery of Laboratory, Clinical, and Community-Based Measures of Head and Trunk Control in People With Acquired VestibulopathyTerminatedNCT04594057Not applicable1 country
- Vestibular Outcomes in Vestibular SchwannomaActive, not recruitingNCT033468891 country
- Auditory Nerve Test System During Vestibular Schwannoma ResectionCompletedNCT04241679Not applicable1 country
- Gamma Knife Radiosurgery vs Initial Conservative Treatment for Vestibular Schwannoma Patients With Preserved Hearing, a Prospective Randomized StudyCompletedNCT01938677Not applicable1 country
- Study of RAD001 for Treatment of NF2-related Vestibular SchwannomaTerminatedNCT01345136Phase 21 country